FDA Halts Use of Most Monoclonal Antibodies for COVID Treatment

The monoclonal antibody combinations bamlanivimab/etesevimab and casirivimab/imdevimab (REGEN-COV) should only be used for COVID-19 patients exposed to variants other than Omicron, the FDA said on Monday.

The agency revised the emergency use authorization (EUA) for the two antibody cocktails for use “only when the patient is likely to have been infected with or exposed to a variant that is susceptible to these treatments,” Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, said in the statement.

FDA cited “markedly reduced activity against the Omicron variant” as the reason for this revision. In addition, because CDC data indicate that over 99% of U.S. COVID cases are from Omicron, “it’s highly unlikely that COVID-19 patients … are infected with a variant other than Omicron, and these treatments are not authorized to be used at this time,” Cavazzoni added.

This action by the agency formalizes the recommendation made at the end of December by the NIH COVID Treatment Guidelines panel, which advised against the use of any monoclonal antibody treatment, with the exception of sotrovimab for high-risk COVID patients, as it was the only one with in vitro efficacy against Omicron.

FDA recommended sotrovimab and other non-monoclonal antibody therapies for outpatients at high risk of progressing to severe COVID, such as oral antiviral nirmatrelvir-ritonavir (Paxlovid), intravenous antiviral remdesivir (Veklury), and oral antiviral molnupiravir, which are “expected to work” against Omicron and are authorized for this high-risk patient population with mild to moderate COVID-19, according to Cavazzoni.

The agency noted that this action avoids exposing patients to side effects, some potentially serious, such as injection site reactions or allergic reactions from a treatment that “is not expected to provide benefit” against Omicron.

  • author['full_name']

    Molly Walker is deputy managing editor and covers infectious diseases for MedPage Today. She is a 2020 J2 Achievement Award winner for her COVID-19 coverage. Follow

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Exercise: A New Breast Cancer ‘Drug'? thumbnail

Exercise: A New Breast Cancer ‘Drug’?

The last thing Liz O’Riordan wanted to do after being diagnosed with stage III breast cancer was exercise. She did it anyway.“I ran 5Ks with a bald head. I cycled to chemo, swam, and did a pool-based sprint-distance triathlon halfway through treatment -- very slowly,” says O’Riordan, who was 40 and a breast cancer surgeon…
Read More
Meta’s New Ray-Ban Glasses Looks More Chic Than Geek thumbnail

Meta’s New Ray-Ban Glasses Looks More Chic Than Geek

Charles Leclerc is the new face of Zuckerberg’s latest unveiling. Just when the wearable tech revolution seemed to have lost some momentum, Meta came up with a new line of smart glasses, and it’s not called Stories. In association with EssilorLuxottica, they have launched the Ray-Ban Meta smart glasses that are available for pre-order and
Read More
PICTURES thumbnail

PICTURES

Hier zeigt und beschreibt die Fotostiftung Schweiz Highlights aus ihrer Sammlung Gipsfüsse Alberto Giacometti im Atelier in Paris, um 1960. Ernst Scheidegger / © 2021 Stiftung Ernst Scheidegger-Archiv, / Fotostfitung SchweizDas klassische Künstleratelier ist ein inspirierender Ort: ein Raum, in dem Ideen und Phantasien materielle Gestalt annehmen, von Kreativität durchdrungen und meist voller Spuren, die…
Read More
Index Of News
Total
0
Share